Amgen hands back heart failure programme rights to Cytokinetics
admin 24th November 2020 Uncategorised 0Omecamtiv mecarbil and AMG 594 rights transitioned back to biotech
More: Amgen hands back heart failure programme rights to Cytokinetics
Source: News
